Background: Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first-line hormonal therapy for patients with advanced breast cancer. Objective: This paper presents the results of an economic evaluation comparing letrozole and tamoxifen as...